Subscribe

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)

CNY24.84 +0.79 (+3.28%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address Building A 200233
Shanghai, SH, CN
CEO Yi Liu
Website fosunpharma.com
IPO 1998-08-07
ISIN CNE000000X38

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 2196.HK (HKD) Other OTC · SFOSF (USD) Shanghai Stock Exchange · 600196.SS (CNY)
Description

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY24.84 +0.79 (+3.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
21M
Beta
0.34
Float Shares
1.64B
Free Float %
62.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.20% -0.51% -6.59% -12.20% -14.30% -12.23% -8.36% -25.46% -66.50% +24.73% +757.93%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
24.84
DCF (Unlevered) 12.86 -48.2%
DCF (Levered) 40.62 +63.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 69% Bullish
Rating 2024-11 Change
Strong Buy 6 0
Buy 5 0
Hold 4 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.38
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +1.1% Q1'26: +6.9% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +22.1% ★ Q1'26: +14.7% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -0.4% Q1'26: +0.6% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +6.1% Q1'26: +16.4% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +2.5% Q1'26: +6.0% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -0.6% ★ Q1'26: -0.7% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    6.02× Q1'26: 6.03× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.41) × ERP
WACC = 63% × Ke + 37% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 12.86 Current price: 24.84
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
5 EPS Ana. 		Dec 2027
6 Rev. Ana.
6 EPS Ana. 		Dec 2028
6 Rev. Ana.
6 EPS Ana.
Revenue
12.61B
est: 12.82B (-1.7%)
14.63B
est: 14.76B (-0.9%)
18.53B
est: 17.53B (+5.7%)
24.92B
est: 24.22B (+2.9%)
28.59B
est: 29.42B (-2.8%)
30.31B
est: 32.08B (-5.5%)
39.01B
est: 36.58B (+6.7%)
43.95B
est: 45.07B (-2.5%)
41.40B
est: 40.47B (+2.3%)
41.07B
est: 42.34B (-3.0%)
41.50B
est: 41.10B (+1.0%)
43.81B
43.50B – 44.47B
+6.6% YoY
45.47B
42.07B – 47.89B
+3.8% YoY
48.27B
48.01B – 48.54B
+6.2% YoY
EBITDA
2.05B
est: 1.53B (+34.1%)
2.39B
est: 1.76B (+35.9%)
3.14B
est: 2.09B (+50.0%)
3.55B
est: 2.89B (+22.9%)
3.68B
est: 3.51B (+4.8%)
4.08B
est: 3.82B (+6.8%)
4.18B
est: 4.36B (-4.1%)
5.54B
est: 5.37B (+3.1%)
3.88B
est: 7.63B (-49.1%)
5.51B
est: 7.99B (-31.0%)
6.10B
est: 7.75B (-21.3%)
8.26B
8.20B – 8.39B
+6.6% YoY
8.57B
7.93B – 9.03B
+3.8% YoY
9.10B
9.05B – 9.15B
+6.2% YoY
EBIT
1.40B
est: 846.92M (+65.7%)
1.67B
est: 974.97M (+70.9%)
2.21B
est: 1.16B (+90.7%)
2.23B
est: 1.60B (+39.3%)
2.38B
est: 1.94B (+22.5%)
2.62B
est: 2.12B (+23.6%)
2.54B
est: 2.42B (+5.0%)
3.42B
est: 2.98B (+14.9%)
1.18B
est: 2.47B (-52.0%)
2.97B
est: 2.58B (+15.3%)
2.52B
est: 2.50B (+0.8%)
2.67B
2.65B – 2.71B
+6.6% YoY
2.77B
2.56B – 2.92B
+3.8% YoY
2.94B
2.93B – 2.96B
+6.2% YoY
Net Income
2.46B
est: 2.81B (-12.5%)
2.81B
est: 3.28B (-14.6%)
3.12B
est: 3.53B (-11.5%)
2.71B
est: 2.99B (-9.5%)
3.32B
est: 3.79B (-12.2%)
3.66B
est: 3.66B (0.0%)
4.73B
est: 4.62B (+2.3%)
3.73B
est: 3.87B (-3.7%)
2.39B
est: 1.83B (+30.1%)
2.77B
est: 2.71B (+2.1%)
3.37B
est: 3.28B (+2.8%)
3.90B
3.86B – 3.94B
+18.9% YoY
4.40B
3.73B – 4.76B
+12.8% YoY
4.83B
4.14B – 5.52B
+9.9% YoY
SGA
4.67B
est: 4.19B (+11.5%)
5.99B
est: 4.83B (+24.1%)
7.51B
est: 5.73B (+31.1%)
10.73B
est: 7.92B (+35.5%)
12.44B
est: 9.62B (+29.3%)
11.12B
est: 10.49B (+6.1%)
12.33B
est: 11.96B (+3.1%)
13.00B
est: 14.74B (-11.8%)
14.09B
est: 12.75B (+10.5%)
12.96B
est: 13.34B (-2.8%)
12.76B
est: 12.95B (-1.4%)
13.80B
13.70B – 14.01B
+6.6% YoY
14.32B
13.25B – 15.09B
+3.8% YoY
15.21B
15.13B – 15.29B
+6.2% YoY
EPS
1.07
est: 1.06 (+1.3%)
1.21
est: 1.23 (-1.9%)
1.27
est: 1.33 (-4.2%)
1.07
est: 1.12 (-4.7%)
1.30
est: 1.42 (-8.5%)
1.43
est: 1.38 (+4.0%)
1.85
est: 1.74 (+6.6%)
1.43
est: 1.45 (-1.7%)
0.89
est: 0.69 (+29.6%)
1.04
est: 1.03 (+1.0%)
1.27
est: 1.24 (+2.0%)
1.47
1.46 – 1.49
+18.4% YoY
1.67
1.41 – 1.80
+13.5% YoY
1.85
1.56 – 2.08
+10.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-28 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-27 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-26 B+ 3/5 4/5 3/5 4/5 1/5 2/5 4/5
2026-05-25 B+ 3/5 4/5 3/5 4/5 1/5 2/5 4/5
2026-05-22 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-21 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-20 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-19 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-18 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-15 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-14 B+ 3/5 4/5 4/5 4/5 1/5 2/5 4/5
2026-05-13 B+ 3/5 4/5 3/5 4/5 1/5 2/5 4/5
2026-05-12 B+ 3/5 4/5 3/5 4/5 1/5 2/5 4/5
2026-05-11 B+ 3/5 4/5 3/5 4/5 1/5 2/5 4/5
2026-05-08 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-05-07 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-05-06 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-30 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-29 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-24 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-22 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.47B
OE per share TTM
0.94
Owner's Yield
4.03%
Maintenance CapEx ratio
90.08%
Maint CapEx / Avg PPE
47.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 139 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 KraneShares MSCI All China Health Care Index ETF KURE 1.26% 999.0K 0.79%
2 Amundi MSCI EM Asia SRI Climate Paris Aligned UCITS ETF DR (D) SADA.L 0.34% 730.4K 0.25%
3 Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C) MSRU.L 0.25% 7.09M 0.25%
4 Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (D) MSDU.L 0.25% 7.09M 0.25%
5 Rayliant-ChinaAMC Transformative China Tech ETF CNQQ 0.24% 53.3K 0.75%
6 JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L 0.23% 53.2K 0.40%
7 HSBC MSCI China A UCITS ETF HMCT.L 0.14% 190.0K 0.30%
8 Xtrackers Harvest CSI 300 China A-Shares ETF ASHR 0.13% 1.71M 0.65%
9 Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L 0.11% 351.1K 0.65%
10 Samsung KODEX China CSI300 ETF 283580.KS 0.11% 213.0K 0.12%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
62.9K
Shares Outstanding
2.64B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Xiaohui Guan Executive Co-Chairman 15M female
Yuqing Chen Executive Chairman 12M male
Deyong Wen Executive Vice Chairman 9M male
Kexin Wang Executive Director — male
Lilang Lu VP, Co-CEO of Fosun MedTech Division & Co-CEO of the Diagnostic Technology Division — female
Rongli Feng Executive President & Chief Human Resources Officer — female
Wang Xingli Co-President & CEO of the Innovative Drugs Business Unit — male
Wenjie Zhang Co-President & Co-CEO of Innovative Medicines Division — male
Yi Liu President, CEO, Co-Chair of the Innov Drugs, Chair, CEO of the Diag & Therap Tech & Exec Director — male
Yuan Fangbing VP & Chief Strategic Enablement Officer — male
Yue Zhu Vice President & GM of Legal Department — female
Zhanyu Chen Senior Vice President & Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic